Danaher Stock Plunge Does Not Represent A Good Entry Point

Danaher Stock Plunge Does Not Represent A Good Entry Point

Seeking Alpha • Jan 30, 2026

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the pharmaceutical market and reduced policy uncertainties offset weakness in academic research funding.

Reuters • Jan 28, 2026

Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript

Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Jan 28, 2026

Danaher Reports Fourth Quarter and Full Year 2025 Results

WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

PRNewsWire • Jan 28, 2026

Danaher Expects Gradual Improvement In End-Market Conditions

Danaher Corp (NYSE: DHR) on Wednesday reported fourth-quarter 2025 sales of $6.84 billion, up 4.5% year-over-year, beating the consensus of $6.81 billion.

Benzinga • Jan 28, 2026

Danaher (DHR) Beats Q4 Earnings and Revenue Estimates

Danaher (DHR) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.14 per share a year ago.

Zacks Investment Research • Jan 28, 2026

Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Jan 28, 2026

Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

DHR beats Q4 estimates as sales rise 4.5%, driven by strength across Life Sciences, Diagnostics and Biotech, and issued upbeat 2026 earnings guidance.

Zacks Investment Research • Jan 28, 2026

Sell Alert: 2 REITs Getting Too Risky

Not all REITs are well-positioned going into 2026. On the contrary, some have become very risky. I present two good examples of that.

Seeking Alpha • Jan 26, 2026

Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

DHR is set to report Q4 results on Jan. 28, with revenues seen up 3.9% and bioprocessing and diagnostics strength in focus.

Zacks Investment Research • Jan 23, 2026